eMeasure Title

Pregnant women that had HBsAg testing

eMeasure Identifier (Measure Authoring Tool) 158 eMeasure Version number 6.0.000
NQF Number Not Applicable GUID 3bbfc929-50c8-44b8-8d34-82be75c08a70
Measurement Period January 1, 20XX through December 31, 20XX
Measure Steward Optum
Measure Developer Optum
Endorsed By None
This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy
This measure is copyrighted by Optum, Inc.  All rights reserved.
The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Optum, Inc. No part of this documentation may be translated to another program language without the prior written consent of Optum, Inc.

Optum(R), Symmetry(R), EBM Connect(R), service marks and logos are registered and unregistered trademarks of Optum and its affiliates in the United States and other countries. 

CMS has contracted with Mathematica Policy Research and its subcontractor, Telligen, for the continued maintenance of this electronic measure.

EBM Connect(R), Release 9.0, 2015.

Due to technical limitations, registered trademarks are indicated by (R) or [R].
Measure Scoring Proportion
Measure Type Process
Risk Adjustment
Rate Aggregation
The U.S. Preventive Services Task Force (USPSTF) found good evidence that universal prenatal screening for hepatitis B virus (HBV) infection using hepatitis B surface antigen (HBsAg) substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection (USPSTF 2009). The current practice of vaccinating all infants against HBV infection and post-exposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection.
Clinical Recommendation Statement
The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit (USPSTF 2009). This is a grade A* recommendation from the USPSTF. In addition, the American College of Obstetricians and Gynecologists (ACOG) recommend screening all pregnant women for HBV infection (ACOG 2007).
Improvement Notation
Higher score indicates better quality
U.S. Preventive Services Task Force. Screening for Hepatitis B Virus Infection in Pregnancy: U.S.Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Int Med 2009;150:869-73.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007;110:941-56.[PMID: 17906043]
Transmission Format
Initial Population
All female patients aged 12 and older who had a live birth or delivery during the measurement period
Equals Initial Population
Denominator Exclusions
Patients who were tested for hepatitis B surface antigen (HBsAg) during pregnancy within 280 days prior to delivery
Numerator Exclusions
Not Applicable
Denominator Exceptions
Patients with a diagnosis of hepatitis B that started or ended within 365 days prior to delivery
Supplemental Data Elements
For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Table of Contents

Population Criteria

Data Criteria (QDM Variables)

Data Criteria (QDM Data Elements)

Supplemental Data Elements

Risk Adjustment Variables

Measure Set